A RCT, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heattreated Bifidobacterium longum CECT 7347 (HT- ES1) in participants with diarrhea-predominant irritable bowel syndrome
This trial determines the efficacy of the probiotic Bifidobacterium longum CECT 7347 (ES1) and postbiotic
heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in improving symptom severity in adults
with diarrhea-predominant irritable bowel syndrome (IBS-D). Two capsules of either
ES1, HT-ES1 or placebo were administered orally, once daily, for 84 days (12 weeks). The primary
outcome was change in total IBS-Symptom Severity Scale (IBS-SSS) score from baseline, compared to
placebo. Secondary outcome measures were stool consistency, quality of life, abdominal pain
severity and anxiety scores.
